219298-74-5

Basic information

• Product Name: 2'-HYDROXY-3,4,5,6'-TETRAMETHOXYCHALCONE
• Synonyms: 2'-HYDROXY-3,4,5,6'-TETRAMETHOXYCHALCONE;(2E)-3-(2-Hydroxy-3,4,5,6-tetramethoxyphenyl)-1-phenyl-2-propen-1-one;3-(2-Hydroxy-3,4,5,6-tetraMethoxyphenyl)-1-phenylprop-2-en-1-one
• CAS NO: 219298-74-5
• Molecular Formula: C19H20O6
• Molecular Weight: 344.36
• Mol File: 219298-74-5.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2'-HYDROXY-3,4,5,6'-TETRAMETHOXYCHALCONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2'-HYDROXY-3,4,5,6'-TETRAMETHOXYCHALCONE(219298-74-5)
• EPA Substance Registry System: 2'-HYDROXY-3,4,5,6'-TETRAMETHOXYCHALCONE(219298-74-5)

Safety Data

• Hazardous Substances Data: 219298-74-5(Hazardous Substances Data)

Usage

General Description

2'-Hydroxy-3,4,5,6'-tetramethoxychalcone is a chemical compound that belongs to a class of organic compounds known as chalcones. It is a natural product found in various plants and possesses antioxidant, anti-inflammatory, and anti-cancer properties. 2'-HYDROXY-3,4,5,6'-TETRAMETHOXYCHALCONE has been studied for its potential therapeutic applications in treating various diseases. Research has shown that 2'-hydroxy-3,4,5,6'-tetramethoxychalcone has the ability to inhibit the growth of cancer cells and reduce inflammation by targeting specific molecular pathways. Additionally, it has been found to have neuroprotective effects and may hold promise for the development of new drugs for the treatment of neurodegenerative diseases.

Relevant articles and documents

Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones

The invention relates to the use of 1,3-bis-aromatic-prop-2-en-1-ones (chalcones), 1,3-bis-aromatic-propan-1-ones (dihydrochalcones), and 1,3-bis-aromatic-prop-2-yn-1-ones for the preparation of pharmaceutical compositions for the treatment or prophylaxis of a number of serious diseases including i) conditions relating to harmful effects of inflammatory cytokines, ii) conditions involving infection by Helicobacter species, iii) conditions involving infection by viruses, iv) neoplastic disorders, and v) conditions caused by microorganisms or parasites. The invention also relates to novel chalcones and dihydrochalcones (especially alkoxy substituted variants) having advantageous substitution patterns with respect to their effect as drug substances, and to methods of preparing them, as well as to pharmaceutical compositions comprising the novel chalcones. Moreover, the present invention relates to a method for the isolation of Leishmania fumarate reductase, QSAR methodologies for selecting potent compounds for the above-mentioned purposes.